The effect of aerobic exercise on serum level of liver enzymes and liver echogenicity in patients with non-alcoholic fatty liver disease

Similar documents
American Journal of Oral Medicine and Radiology

Downloaded from zjrms.ir at 3: on Monday February 25th 2019 NAFLD BMI. Kg/m2 NAFLD

Prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar

International Journal of Current Research and Academic Review ISSN: Volume 3 Number 9 (September-2015) pp

Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup

Evaluation of carotid intima-medial thickness as a marker of atherosclerosis in patients with non-alcoholic fatty liver disease

ALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche,

Association between Non-Alcoholic Fatty Liver Disease and Carotid Intima-Media Thickness in Overweight and Obese Children

CDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health

At Least 1 in 5 Patients in Your Practice Have Fatty Liver

NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012

Nonalcoholic Fatty Liver Disease in a Sample of Iranian Women with Polycystic Ovary Syndrome

Assessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study

Laboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011

Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.

Disclosure. Objectives. Smash the Nash: A practical approach to fatty liver disease

EFFECT OF ORAL SUPPLEMENTATION OF WHEY PROTEIN ISOLATE ON NON-ALCOHOLIC STEATOHEPATITIS PATIENTS

Non-Alcoholic Fatty Liver Diseasean underestimated epidemic

Non-alcoholic fatty liver disease and associated risk factors among hemodialysis patients

Non-Alcoholic Fatty Liver Disease

Internal and Emergency Medicine Official Journal of the Italian Society of Internal Medicine. ISSN Volume 8 Number 3

Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology

Background of the FIB-4 Index in Japanese Non-Alcoholic Fatty Liver Disease

Challenges in the Diagnosis of Steatohepatitis

NASH PROGRESS IN THE LAST DECADE

Non-alcoholic fatty liver disease (NAFLD) is a

The classical metabolic work-up, approved by the Ethics Committee of the Antwerp

Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease

What is NAFLD?.NASH? Presenter Disclosure Information. Learning Objectives. Case 1: Rob. Questions Pertinent to Rob

Improving Access to Quality Medical Care Webinar Series

Learning Objectives. Disclosures. Self Assessment Questions. Background

The Egyptian Journal of Hospital Medicine (Apr. 2017) Vol. 67(1), Page

Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI

Development and validation of a simple index system to predict nonalcoholic fatty liver disease

Fatty liver disease: What do we know?

Abdominal Obesity and Fatty Liver

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease

Higher non-hdl-cholesterol to HDLcholesterol ratio linked with increased nonalcoholic steatohepatitis

Recognition of Reversible Liver Disease: A Window of Opportunity in the Metabolic Syndrome Epidemic

Assessment of NAFLD cases and its correlation to BMI and metabolic syndrome in healthy blood donors in Kerman

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy

Hepatitis C Virus Infection in Diabetes Mellitus Patients

NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES

Non-alcoholic Fatty Liver Disease and its Predictive Factors Among High-Risk Employees of Health Insurance Organization in Tabriz, Iran

LIVER, PANCREAS, AND BILIARY TRACT

La sindrome metabolica e il suo impatto dopo la guarigione nel paziente HIV/HCV

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE

Serum leptin levels in psoriatic patients with non-alcoholic fatty liver disease

Non alcoholic fatty liver disease and atherosclerosis Raul Santos, MD

CLINICAL AND HISTOLOGICAL FEATURES OF NON-ALCOHOLIC STEATOHEPATITIS IN IRANIAN PATIENTS

Fatty Liver Disease. Mark Thursz. Imperial College

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

Steatotic liver disease

Update on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic

What to do about the high ALT picked up at the annual review. Dr Michael Yee Consultant in Diabetes and Endocrinology

Fatty liver disease in Sudan is not alcohol related Nail A M 1, Gadour MO 2, Khair MM 3, Salma BM 4, Suzan E 5

Non alcoholic fatty liver and Non alcoholic Steatohepatitis. By Dr. Seham Seif

Risk Factors for Progression of and Treatment Options for NAFLD in Children

The association between white blood cell subtypes and prevalence and incidence of nonalcoholic fatty liver disease

The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis

Prevalence of non-alcoholic fatty liver disease in type-2 diabetes mellitus patients

Incidence of Non-alcoholic Fatty Liver Disease among Referral Outpatients to the Internal Medicine Clinic

NAFLD AND TYPE 2 DIABETES

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

EVALUATION OF ABNORMAL LIVER TESTS

UMHS-PUHSC JOINT INSTITUTE

Supplementary Table 1. The distribution of IFNL rs and rs and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC

The Efficacy of Corticosteroid Therapy in a Patient with Nonalcoholic Steatohepatitis Overlapping Autoimmune Hepatitis: A Case Report

One-Year Intense Nutritional Counseling Results in Histological Improvement in Patients with Nonalcoholic Steatohepatitis: A Pilot Study

Case #1. Digital Slides 11/6/ year old woman presented with abnormal liver function tests. Liver Biopsy to r/o autoimmune hepatitis

Hepatology for the Nonhepatologist

Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam , Republic of Korea 2)

NON-ALCOHOLIC FATTY LIVER DISEASE:

3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H.

Normal ALT for men 30 IU/L 36% US males abnormal. Abnl ALT. Assess alcohol use/meds. Recheck in 6-8 weeks. still pos

Pancreatic exocrine insufficiency: a rare cause of nonalcoholic steatohepatitis

Liver disease is a major cause of mortality and morbidity

DIABETES AND LABORATORY TESTS. Author: Josephine Davis

Correlation between bright echogenic liver, elevated liver enzymes and liver histology.

PREVALENCE OF NAFLD & NASH

Pentoxifylline for Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) : A Randomized, Placebo-Controlled Study ABSTRACT

Prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetic patients in correlation with coronary artery disease

Original. Kouki MASUO 1, Hitoshi FUNAGI 2 and Kunihiko KAWAI 2

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical

Kynamro. Kynamro (mipomersen) Description

JMSCR Vol 06 Issue 12 Page December 2018

NONALCOHOLIC FATTY LIVER DISEASE

«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin

Clinical study of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus

A Hospital Based Study Correlating the Prevalence of Fatty Liver Disease in Polycystic Ovary Syndrome using Ultra Sound as Screening Modality

FREQUENCY OF NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND ITS BIOCHEMICAL DERANGEMENTS IN TYPE II DIABETIC PATIENTS

Alarming high levels of transaminases in non insulin dependent diabetes mellitus

The Skinny On Non Alcoholic Fatty Liver Disease

A Modification of the Brunt System for Scoring Liver Histology of Patients with Non-Alcoholic Fatty Liver Disease

OBESITY IN PRIMARY CARE

Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014

Thyroid Function and Risk of Non-Alcoholic Fatty Liver Disease in Euthyroid Subjects

Transcription:

Gastroenterology and Hepatology From Bed to Bench. 2013 RIGLD, Research Institute for Gastroenterology and Liver Diseases ORIGINAL ARTICLE The effect of aerobic exercise on serum level of liver enzymes and liver echogenicity in patients with non-alcoholic fatty liver disease Manouchehr Khoshbaten 1, Yaghoub Salekzamani 2, Nasrin Gholami 1, Maryam Zareh Nahandi 1, Saied Sokhtehzari 3, Amir Hossein Monazami 4, Mazhar Rostami Nejad 5 1 Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 2 Physical Medicine and Rehabilitation Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 3 Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran 4 Faculty of Physical Education, Tehran University, Tehran, Iran 5 Islamic Azad University, Central Tehran Branch, Tehran, Iran ABSTRACT Aim: The aim of this study was to evaluate the effect of an aerobic exercise on serum level of liver enzymes and liver echogenicity in patients with non-alcoholic fatty liver disease. Background: Non-alcoholic fatty liver disease (NAFLD) has different prevalence in various parts of the world. Obesity and low physical activity are main risk factors for the development of NAFLD. Patients and methods: Ninety patients diagnosed by ultrasound as NAFLD was evaluated in a clinical trial as case (A) and control groups (B). The effect of aerobic exercise on changing the liver enzymes and liver echogenicity was assessed in cases compared with control group which were only on medical therapy. Results: The mean age in the sample group was 37.6±8.3 in the 17-56 yrs age range. In group A, fatty liver was in stage I in 26 (57.8%) cases, stage II in 17 (37.8%), and stage III in 2 (4.4%). In group B, fatty liver was in stage I in 30 (66.7%) patients, in stage II in 14 (31.1%) and stage III in 1 (2.2%). After an aerobic exercise, serum level of liver enzymes and liver echogenicity in patients with non-alcoholic fatty liver disease was significant improved in case group (ALT (P= 0.0001), AST (P=0.01). Conclusion: Considering the present study, we can suggest that a controlled aerobic exercise schedule can be helpful in association of medical therapy in the treatment of NAFLD. Keywords: Liver enzyme, NAFLD, Aerobic exercise. (Please cite as: Khaoshbaten M, Salekzamani Y, Gholami N, Zareh Nahandi M, Sokhtehzari S, Monazami AH, et al. The effect of aerobic exercise on serum level of liver enzymes and liver echogenicity in patients with non alcoholic fatty liver disease. ). Introduction 1 Non-alcoholic fatty liver disease (NAFLD) is a liver disorder that is accompanied with accumulation of triglyceride in hepatocyte. Pathologic changes in non-alcoholic fatty liver disease are similar to alcoholic fatty liver disease, Received: 12 April 2013 Accepted: 18 July 2013 Reprint or Correspondence: Mazhar Rostami Nejad, BS. Islamic Azad University, Central Tehran Branch, Tehran, Iran. E-mail: m_rostami_n@ymail.com but there is not any alcohol consumption or less than limit that can damage the hepatocyte. These changes are in a spectrum from simple steatosis to steatohepatitis and finally fibrosis and then cirrhosis (1-5). NAFLD has a different prevalence in various parts of the world, though 20-30% prevalence has been reported in epidemiologic studies in western

Khoshbaten M. et al S113 countries (2, 6-8). This disease can be seen in all ages but often middle-aged people are affected (8). Now there are multiple methods for the diagnosis of NAFLD in the world. Sonography is one of these methods that are applied to the diagnosis of this disease with ruling out other probable diseases (9). NAFLD is related to metabolic syndrome such as obesity, diabetes mellitus and hyperlipidemia. Since obesity and low physical activity are main risk factors for the development of NAFLD, life style modification considering weight loss and physical activity is thought to be an important alternative for treatment of this disease (10). A few studies performed regarding the quantity of the physical activity in NAFLD. But the advantages of physical activity have been shown very clearly (11). With considering this reality surveying on specific affects of physical activity on non-alcoholic fatty liver disease in the site of research is necessary. Therefore, the aim of present study was to evaluate the effect of an aerobic exercise on serum level of liver enzymes and liver echogenicity in patients with nonalcoholic fatty liver disease. Patients and Methods In this non-randomized clinical trial including 90 patients with established NAFLD divided equally in to case and control groups. The duration of this study was 12 months from December 2011 until December 2012. For the diagnosis of this disease, sonography with acceptable sensitivity and specificity was applied. Before entering a patient to the study the height and weight of patient with minimal cloths was measured in both groups. For measuring of height and weight SECA balance device has been used with the accuracy of 0.5 cm and 0.1 kg. Body Mass Index (BMI) was calculated with using of weight/height 2 in the start of the study in both groups. Also body composition of any patient in each group was determined in the start and the end of the study with the device of ZEUS9 bioelectrical impedance analysis. At the beginning of the study the measuring of liver enzymes (AST, ALT, ALP) and FBS and lipid profile (TG, Total cholesterol, HDL cholesterol) with enzymatic methods was measured. The level of LDL cholesterol was calculated with the formula of Fredwald, but if the level of TG was more than 400 mg/dl, enzymatic methods were applied for the measuring of LDL cholesterol. On the other hand, in control group medical therapy with 1000 mg vitamin C and 400 units vitamin E was prescribed. In case group in addition to the medical therapy similar to control group, thirty minutes aerobic exercise with maximal heart rate three times a week with the duration of three months was performed. At the end of the study, variation of the variables (mentioned above) in cases was compared with control group. Patients with alcohol consumption more than 20cc per day, drug usage, viral hepatotropic positive or Wilson s disease, autoimmune disease, cholestatic disorders, renal, cardiovascular or thyroid disease, and patients with history of gastric bypass surgery, parenteral nutrition or cachexia were excluded from this study. Statistical analysis The results of the study represented as mean ± standard deviation (SD), percentage and abundance using SPSS software version 16. For the comparison of quantitative variables student t-test and for the comparison of qualitative variables chi-square has been applied and in the cases in which predictive value was less than 0.05, the result was recognized significant. Results Totally 57 subjects (63/3%) were male and 33 subjects (36.7%) were female. In group A (case

S114 The effect of aerobic exercise in patients with NAFLD group) 29 (64/4%) were male and 16 (35/6%) were female and in group B (control group) 28 individuals (62/2%) and 17 persons (37/8%) were male and female respectively. The mean age of entire patients was 37.6±8.3 ranged between 17-56 years old. The mean age in cases and control was 35.6±9.2 (17-54) and 39.5±6.9 (26-56) years old respectively. The statistical analysis showed a significant difference regarding mean age in two groups (P=0.02). Basic data in studied groups are presented in table 1. Table 1 showed no statistically difference in cases compare to controls. Also table 2 showed that the mean of biochemical test in cases before and after an aerobic exercise only for ALT and AST was significant. Table 1. Basic data in case and control groups Case (n=45) Control (n=45) P-value Height 169.7±11.8 * 168.3±9.9 0.56 (120-188) (147-189) Weight 84.2±1.3 83.9±1.3 0.91 (50-115) (59-120) BMI 28.9±3.2 29.5±4.1 0.47 (22.4-36.8) (23-46.6) DBP 72.8±8.1 (60-90) 76.2±9.8 (60-100) 0.08 * Mean± standard deviation (range); Body mass index; Diastolic blood pressure Table 2. The result of biochemical test in cases before and after an aerobic exercise Variables * Before After P Value FBS 95.2±19.6 95.2±16 P=0.98 (62-193) (66-160) TG 218.2±12 188.6±8.6 P=0.18 (82-687) (36-398) Total Chol 190.6±35.5 194.9±38.8 P=0.58 (124-294) (90-284) LDL 108.1±31.3 112.2±36.1 P=0.57 (49-184) (38-197) HDL 42.4±9.7 45.3±8.8 P=0.14 (27-71) (29-71) AST 41.5±2.7 29±9.5 P=0.006 (13-137) (15-53) ALT 61.1±3.6 44.9±2.4 P=0.01 (14-185) Alk.P 165.9±61.4 (29-338) (13-119) 185±56.2 (45-400) P=0.12 * Mean±SD; FBS: fasten blood sugar; TG: triglyceride; Chol: cholesterol; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase After the completion of aerobic exercise duration in both groups, serum level of liver enzymes and liver echogenicity in patients with non-alcoholic fatty liver disease was decreased. The degree of fatty liver in group A showed fatty stage 1 in 35 patients (77.8%), stage 2 in 4 patients (8.9%) and 6 patients (13.3%) without sonographic fatty liver. In group B fatty liver degree of 33 patients (73.3%) was in stage 1, 9 patients (20%) in stage 2 and fatty liver of 3 patients (6.7%) had been resolved by sonography. The difference in both groups was not statistically significant (P=0.23). Weight, BMI FBS, TG, HDL, AST, ALT and VFM, kg was statistically significant by comparison of basic information description before and after trial in group A (P<0.05) (Table 3). This result was statistically significant in control group for weight, BMI, SBP, DBP, TG and LBM (P<0.05) (Table 4). Table3. The comparison of basic information description before and after trial in group A Variable * Pre Trial Post Trial P Value Weight 84.2±1.3 82.1±11.9 0.0001 BMI 28.9±3.2 28±2.8 0.0001 SBP 112.7±14.9 110.2±11.7 0.06 DBP 72.8±8.1 71.9±14.4 0.35 FBS 95.2±19.6 90.6±14.4 0.01 TG 218.2±12 176±5.2 0.002 Total Chol 190.6±35.5 183.2±25.6 0.09 LDL 108.1±31.3 100±26.2 0.06 HDL 42.4±9.7 46.5±8.1 0.0001 AST 41.5±2.7 34.3±15.1 0.01 ALT 61.1±3.6 43.5±2.4 0.0001 Alk.P 165.9±61.4 157.9±54.2 0.12 VFM, kg 3.8±1 3.7±1.1 0.0001 * Mean± standard deviation FBS: fasten blood sugar; TG: triglyceride; Chol: cholesterol; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase Discussion As our results showed that NAFLD s pathologic changes are similar to pathologic changes that are seen in alcoholic fatty liver

Khoshbaten M. et al S115 disease but there is no alcohol usage in NAFLD (1). NAFLD s prevalence is different worldwide, though 20-30% prevalence has been reported in epidemiologic studies in western countries (2). This disease can be seen in all ages but often middle-aged people are more affected (8). Table 4. The comparison of basic information description before and after trial in group B Variable * Pre Trial Post Trial P Value Weight 83.9±1.3 83.3±12.9 0.02 BMI 29.5±4.1 29.4±4.1 0.04 SBP 127.2±18.3 123.4±17.7 0.0001 DBP 76.2±9.8 72.8±10.8 0.006 FBS 95.2±16 94.3±13.4 0.2 TG 188.6±8.6 172.4±7.6 0.04 Total Chol 194.9±38.8 193.8±34.3 0.6 LDL 112.2±36.1 115.8±26.9 0.6 HDL 45.3±8.8 46±8.4 0.5 AST 29±9.5 28±9.9 0.2 ALT 44.9±2.4 39.9±2.2 0.07 Alk.P 185±56.2 193.2±46.8 0.2 VFM, kg 3.5±1.5 3.3±1.5 0.7 WHR 0.9±0.1 0.9±0.07 0.2 Body Fat, kg 23.2±6.1 22.9±6.8 0.6 LBM 55±9.9 54.9±8.9 0.005 * Mean±SD; FBS: fasten blood sugar; TG: triglyceride; Chol: cholesterol; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase Sotodeh et al. in 2006 studied the effect of aerobic exercise in patients with non-alcoholic fatty liver disease. The finding of this study followed this kind of exercise and showed the decrease of liver enzymes level (12). In this study we showed the statistical significant decrease of AST, ALT and ALP level in NAFLD patients after an aerobic exercise. In addition to the decrease of liver enzymes in our study, the decrease of lipid profile in cases was statistically significant. In another study by Chen et al. in 2008, 23 patients with established NAFLD did intense cycling in duration of 2 hours a week for 10 weeks and they showed that in the end of study the significant decrease in topography index, insulin resistance and sonographic findings (13). Also, in our study body composition components such as body fat mass, visceral fat mass and body mass index and waist to hip ratio had statistical meaningful decrease but we couldn t show the statistically significant decrease in sonographically fat component in our patients. In a cross sectional study by Perseghin et al., the relation between physical activity and the component of liver s fat was reverse (14). In a meta-analytic survey in 2008, physical activity (aerobic or anaerobic) in 375 patients with NAFLD had protective effect such as decrease in lipid profile and body composition (15). In conclusion, with respect to result of this study and comparison with the studies, which is mentioned above we, could conclude that in addition to medical therapy, controlled exercise trial can be helpful in the cure of non-alcoholic fatty liver disease. References 1. Bisceglie AM, Mahachai V, Graham AS. Advances in the understanding and treatment on nonalcoholic fatty liver disease. Drugs 2003; 63: 2379-94. 2. Ruhl CE, Everhart JE. Epidemiology of Nonalcoholic fatty liver. Clin Liver Dis 2004; 8: 501-19. 3. Angulo P. Nonalcoholic Fatty Liver Disease. New England J Med 2002;16:1221-31. 4. Moller DE, Berger JP, Hui JM. Hepatic steatosis and insulin resistance. Pharmacol Ther 2005; 22: 64-70. 5. Das SK, Mukherjee S, Vasudevan DM. Nonalcoholic Fatty liver disease: an under- recognized cause with emerging importance. Curr Sci 2006; 90: 5. 6. Harrison SA, Kadakia S, Schenker S. Nonalcohololic steatohepatitis: what we know in the New Millennium. Am J Gastroenterol 2002;97: 2714-24. 7. Targher G, Zenari L, Bertolini L. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men. Diabetes Care 2004; 27: 2498-500. 8. Neuschwander BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003; 37: 1202-19.

S116 The effect of aerobic exercise in patients with NAFLD 9. Matteoni CA, Younossi ZM, Gramlich T. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-19. 10. Manco M, Bedogni G, Monti L, Morino G, Natali G, Nobili V. Intima-media thickness and liver histology in obese children and adolescents with non-alcoholic fatty liver disease. Atherosclerosis 2010; 209:463-68. 11. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21:3-16. 12. Sotodeh M, Tavangar M, Khadem F. Correlation of the serum levels of the ALT and AST with the degree of inflammation and fibrosis in the liver of patients with non-alcoholic steohapatitis: validation of the revisions applied on the Brunt scoring system. Hakim 2006; 8: 1-8. [In Persian] 13. Chen SM, Liu CY, Huang HT. Effects of therapeutic lifestyle program on ultrasound-diagnosed nonalcoholic fatty liver disease. J Clin Med Assoc 2008; 71:551-58. 14. Perseghin G, Cobelli F, Espositto A. Habitual Physical activity is associated with intrahepatic fat content in humans. Diabetes Care 2007; 30: 683-88. 15. Sagi S, Goldsmith R, Webb M. Role of lisure time physical activity in nonalcoholic fatty liver disease: A population based study. Hepatology 2008; 48: 1791-98.